Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients

Health and Quality of Life Outcomes

Volumn 9, Issue , 2011, Pages

  Walker, Mark S ^a   Hasan, Murad ^a   Mi Yim, Yeun ^b   Yu, Elaine ^b   Stepanski, Edward J ^a   Schwartzberg, Lee S ^c  

^a ACORN Research LLC   (United States)

^b GENENTECH INC   (United States)

^c WEST CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; ERBB2 PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER LOCALIZATION; CANCER PATIENT; CAUCASIAN; DISEASE COURSE; ELECTRONIC MEDICAL RECORD; FATIGUE; FEMALE; HORMONAL THERAPY; HUMAN; HYPERTENSION; LIVER METASTASIS; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; PAIN; PATIENT CARE; PERITONEUM METASTASIS; QUALITY OF LIFE; RETROSPECTIVE STUDY; SELF REPORT; SLEEP DEPRIVATION; TREATMENT OUTCOME; BONE TUMOR; BREAST TUMOR; LIVER TUMOR; LUNG TUMOR; MEDICAL RECORD; METASTASIS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; SICKNESS IMPACT PROFILE; STATISTICAL MODEL; UNITED STATES;

BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LINEAR MODELS; LIVER NEOPLASMS; LUNG NEOPLASMS; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM METASTASIS; QUALITY OF LIFE; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SELF REPORT; SICKNESS IMPACT PROFILE; UNITED STATES;

EID: 79959269990     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-9-46     Document Type: Article

References (36)

1. American Cancer Society Cancer Facts and Figures. 2009, Atlanta, GA: American Cancer Society, Inc., American Cancer Society.
2. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007, 9:R28. 10.1186/bcr1672, 1929089, 17477859.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
4. American Cancer Society Breast Cancer Facts and Figures, 2009 - 2010. 2009, Atlanta, GA: American Cancer Society, Inc., American Cancer Society.
5. Morrogh M, Park A, Norton L, King TA. Changing indications for surgery in patients with stage IV breast cancer: a current perspective. Cancer 2008, 112:1445-1454. 10.1002/cncr.23319, 18306353.
6. Coates AS, Hurny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelber RD, Goldhirsch A. Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol 2000, 18:3768-3774.
7. Knobf MT, Sun Y. A longitudinal study of symptoms and self-care activities in women treated with primary radiotherapy for breast cancer. Cancer Nurs 2005, 28:210-218.
8. Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival: metastatic breast cancer. Ann Oncol 2000, 11:469-474. 10.1023/A:1008396330433, 10847468.
9. Mandelblatt J, Armetta C, Yabroff KR, Liang W, Lawrence W. Descriptive review of the literature on breast cancer outcomes: 1990 through 2000. J Natl Cancer Inst Monogr 2004, 8-44.
10. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008, 27:32. 10.1186/1756-9966-27-32, 2543010, 18759983.
11. Ashing-Giwa KT, Lim JW. Exploring the association between functional strain and emotional well-being among a population-based sample of breast cancer survivors. Psychooncology 2009, 19(2):150-9.
12. Emery CF, Yang HC, Frierson GM, Peterson LJ, Suh S. Determinants of physical activity among women treated for breast cancer in a 5-year longitudinal follow-up investigation. Psychooncology 2009, 18:377-386. 10.1002/pon.1519, 2744438, 19241490.
13. Andersen MR, Bowen DJ, Morea J, Stein KD, Baker F. Involvement in decision-making and breast cancer survivor quality of life. Health Psychol 2009, 28:29-37.
14. Von Ah DM, Kang DH, Carpenter JS. Predictors of cancer-related fatigue in women with breast cancer before, during, and after adjuvant therapy. Cancer Nurs 2008, 31:134-144. 10.1097/01.NCC.0000305704.84164.54, 18490890.
15. Browall M, Ahlberg K, Karlsson P, Danielson E, Persson LO, Gaston-Johansson F. Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women. Eur J Oncol Nurs 2008, 12:180-189. 10.1016/j.ejon.2008.01.005, 18343197.
16. Buijs C, Rodenhuis S, Seynaeve CM, van Hoesel QG, van der Wall E, Smit WJ, Nooij MA, Voest E, Hupperets P, TenVergert EM, van Tinteren H, Willemse PH, Mourits MJ, Aaronson NK, Post WJ, de Vries EG. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. J Clin Oncol 2007, 25:5403-5409. 10.1200/JCO.2007.11.2813, 18048822.
17. Northouse LL, Mood D, Kershaw T, Schafenacker A, Mellon S, Walker J, Galvin E, Decker V. Quality of life of women with recurrent breast cancer and their family members. J Clin Oncol 2002, 20:4050-4064. 10.1200/JCO.2002.02.054, 12351603.
18. Oh S, Heflin L, Meyerowitz BE, Desmond KA, Rowland JH, Ganz PA. Quality of life of breast cancer survivors after a recurrence: a follow-up study. Breast Cancer Res Treat 2004, 87:45-57. 10.1023/B:BREA.0000041580.55817.5a, 15377850.
19. Kenne Sarenmalm E, Ohlen J, Jonsson T, Gaston-Johansson F. Coping with recurrent breast cancer: predictors of distressing symptoms and health-related quality of life. J Pain Symptom Manage 2007, 34:24-39. 10.1016/j.jpainsymman.2006.10.017, 17544244.
20. Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004, 40:1704-1712. 10.1016/j.ejca.2004.03.025, 15251160.
21. Bertsch LA, Donaldson G. Quality of life analyses from vinorelbine (Navelbine) clinical trials of women with metastatic breast cancer. Semin Oncol 1995, 22:45-53. discussion 53-44.
22. Liu J, Tu D, Dancey J, Reyno L, Pritchard KI, Pater J, Seymour LK. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19. Breast Cancer Res Treat 2006, 100:263-271. 10.1007/s10549-006-9257-1, 16823511.
23. Siddiqi A, Given CW, Given B, Sikorskii A. Quality of life among patients with primary, metastatic and recurrent cancer. Eur J Cancer Care (Engl) 2009, 18:84-96.
24. Aranda S, Schofield P, Weih L, Yates P, Milne D, Faulkner R, Voudouris N. Mapping the quality of life and unmet needs of urban women with metastatic breast cancer. Eur J Cancer Care (Engl) 2005, 14:211-222.
25. Fortner B, Okon T, Schwartzberg L, Tauer K, Houts AC. The Cancer Care Monitor: Psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manage 2003, 26:1077-1092. 10.1016/j.jpainsymman.2003.04.003, 14654260.
26. Fortner B, Baldwin S, Schwartzberg L, Houts AC. Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manage 2006, 31:207-214. 10.1016/j.jpainsymman.2005.07.009, 16563315.
27. Houts AC, Lipinski D, Olsen JP, Baldwin S, Hasan M. Use of the patient care monitor to screen for depression in adult cancer patients interviewed with the structured clinical interview for DSM-IV. Psychooncology 2009, 19(4):399-407.
28. Walker MS, Schwartzberg LS, Stepanski EJ, Fortner BV. A retrospective study of quality of life in a community sample of patients with early stage breast cancer. Breast Cancer Res Treat 2009, 115:415-422. 10.1007/s10549-009-0387-0, 19373552.
29. Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ, Ong J, Houts AC. The relation of trouble sleeping, depressed mood, pain and fatigue in patients with cancer. J Clin Sleep Med 2009, 5:132-136. 2670332, 19968046.
30. Littell RC, Pendergast J, Natarajan R. Modelling covariance structure in the analysis of repeated measures data. Stat Med 2000, 19:1793-1819. 10.1002/1097-0258(20000715)19:13<1793::AID-SIM482>3.0.CO;2-Q, 10861779.
31. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 1997, 16:2349-2380. 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E, 9351170.
32. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989, 10:407-415. 10.1016/0197-2456(89)90005-6, 2691207.
33. Copay AG, Subach BR, Glassman SD, Polly DW, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 2007, 7:541-546. 10.1016/j.spinee.2007.01.008, 17448732.
34. Ringash J, O'Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. Cancer 2007, 110:196-202. 10.1002/cncr.22799, 17546575.
35. Taxol drug label. , http://packageinserts.bms.com/pi/pi_taxol.pdf
36. van Draanen J, Stacey E, Dent R, Gallo-Hershberg D, Pasetka M, Giotis A, Kan K, van Draanen L, Fang T, Lee V, Walker S, DeAngelis C. Muscle and joint symptoms in breast cancer patients receiving taxane-based chemotherapy. San Antonio Breast Cancer Symposium 2010, San Antonio, TX.